Tevogen Bio Inc.
(TVGN)
undefined
undefined%
At close: undefined
1.60
4.58%
Pre-market Jan 08, 2025, 05:17 AM EST
Company Description
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.
The company is based in Warren, New Jersey.
Tevogen Bio Inc.
| Country | United States |
| IPO Date | Jan 5, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. |
Contact Details
Address: 15 Independence Blvd Warren, New Jersey United States | |
| Website | https://tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860871 |
| CUSIP Number | n/a |
| ISIN Number | US88165K1016 |
| Employer ID | 98-1597194 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer & Chairman |
| Kirti Desai CPA | Chief Financial Officer |
| Mittul Mehta | Chief Information Officer & Head of Tevogen.ai |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead |
| Sadiq Khan M.B.A. | Chief Commercial Officer |
| Stephen Chen M.B.A. | Chief Technical Officer |
| Tapan V. Shah | Head of Investor Relations & Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | 4 | Filing |
| Dec 26, 2024 | 4 | Filing |
| Dec 26, 2024 | 4 | Filing |
| Dec 26, 2024 | 4 | Filing |
| Dec 26, 2024 | 4 | Filing |
| Nov 19, 2024 | 424B3 | Filing |
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | NT 10-Q | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |